Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05742607 · ClinicalTrials.gov registry record · Phase 2
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Innate Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT05742607 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Innate Pharma. The registered enrollment target is 70 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05742607, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Innate Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG IPH5201 + durvalumab + standard chemotherapy
Study Locations (20)
Other
- Angers University Hospital Center - Angers
- University Hospital Center Caen - Caen
- Hospital Calmette - Lille
- CHU de Limoges - Limoges
- Leon Berard Center - Lyon
- Marseille University Hospital Center - North Hospital - Marseille
- Rennes University Hospital Center - Hospital Pontchaillou - Rennes
- Charles Nicolle Hospital - Rouen
- Gustave Roussy - Villejuif
- Henry Dunant Hospital Center - Athens
- University General Hospital "Attikon" - Athens
- University General Hospital of Ioannina - Ioannina
- University General Hospital of Patras - Pátrai
- Koranyi National Institute of Pulmonology, 14th Department of Pulmonology - Budapest
Florida
- St. Anthony's Hospital - BayCare Health System - St. Petersburg
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Illinois
- University of Chicago Medical Center - Chicago
New York
- Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics - Lake Success
Texas
- Millennium Research & Clinical Development - Houston
Wisconsin
- UW Carbone Cancer Center - Cancer Connect - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-06-23 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05742607
The ClinicalTrials.gov registry entry for NCT05742607 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which IPH5201 + durvalumab + standard chemotherapy is the first listed.
NCT05742607 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05742607 about?
NCT05742607 is a clinical study titled "IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)". The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC...
What is the current status of trial NCT05742607?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2023-06-23. Estimated completion is 2026-09.
What conditions does trial NCT05742607 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05742607?
The interventions under investigation include: IPH5201 + durvalumab + standard chemotherapy (DRUG).
Who is sponsoring clinical trial NCT05742607?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05742607 being conducted?
This trial has 20 study locations across Florida, Illinois, New York, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.